While survival outcomes for Black women improved among all tumor subtypes when GCC was given, racial and ethnic disparities in survival outcomes persisted among patients with hormone receptor–positive/ERBB2-negative and hormone receptor–positive/ERBB2-positive subtypes. This evidence concerns the gene NR4A1 and goblet cell carcinoma.